Aeglea Q3 net loss $18.2M; cash $75.2M; pegtarviliase interim data expected Q4 2022

Spyre Therapeutics, Inc.

2022-Q3 EPS reported -$0.81 revenue$2,161,000

Cash, equivalents and securities total $75.2M as of Sept 30, 2022; runway into Q4 2023.
Net loss $18.2M vs $20.3M in Q3 2021; revenue $0.2M from Immedica license.
Phase 1/2 pegtarviliase trial for Homocystinuria dosing cohort 3 at 1.35 mg/kg; interim data planned Q4 2022.
MAA for pegzilarginase (Arginase 1 Deficiency) submitted by partner Immedica currently under EMA review.
Corporate restructuring announced; Jim Kastenmayer appointed interim CEO; permanent CEO search underway.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spyre Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.2 million.

Period: the third quarter ended September 30, 2022
Revenue: $0.2 million
Result: reported results

Exact text from the filing

securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023. Aeglea recognized development fee revenues of $0.2 million in the third quarter of 2022 as a result of its license and supply agreement with Immedica for the commercial rights to pegzilarginase in certain territories outside the U.S. The

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021527

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.